Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 15 June 2022
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 June 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 February 2024
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 December 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 June 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 April 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 May 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 March 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 February 2022
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (TA750)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 October 2021
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 September 2021
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 September 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 July 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Avelumab for treating metastatic Merkel cell carcinoma (TA517)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 April 2021Published: 11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 April 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 March 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 March 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 February 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 January 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 October 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 September 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2020
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2019
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Padeliporfin for untreated localised prostate cancer (TA546)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 November 2018
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 July 2018
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 May 2018
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2017
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2017
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 25 September 2017Published: 29 March 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 25 November 2015
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2017
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2017
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 March 2017Published: 14 December 2011
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 August 2016Published: 25 May 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 April 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 February 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2015Published: 12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2014
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 April 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2014
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2012
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 October 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2012Published: 24 January 2007
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 February 2011
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2010
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2010
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2009
Gemcitabine for the treatment of metastatic breast cancer (TA116)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2006
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2003
Fruquintinib for previously treated metastatic colorectal cancer ID6274Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 September 2024
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 27 June 2024Expected publication date: 25 September 2024
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 September 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC